Search results for "MFI"

Breve demostracion de la justicia, que assiste a Don Joseph de Ribera Borja y Llanzol, regidor perpetuo, y mas antiguo de esta Ciudad de Valencia. En…

1739

A continuació de l'imprès, [3] p. mss. sobre el mateix plet Sobre el tít.: "Jesus, Maria, Joseph, y Francisco de Paula" Signat al final: "Dr. D. Pedro Albornoz y Tapies" Caplletra ornada al començament del text Sign.: A-B2, C1 Reclams

Amfifīlu 1,4-dihidropiridīna atvasinājumu 2,6-vietu modificēšana un to pašasociējošo īpašību pētījumi

2017

Amfifīlu 1,4-dihidropiridīna atvasinājumu 2,6-vietu modificēšana un to pašasociējošo īpašību pētījumi. Ragže J., darba vadītājs Dr.chem., vadošais pētnieks Pajuste K. Bakalaura darbs, 46 lappuses, 10 attēli, 5 tabulas, 59 literatūras avoti, 1 pielikums. Latviešu valodā. Raksturota šķīdinātāja ietekme “klika” reakcijai ar didodecil 2,6-bis(azidometil)-4-fenil-1,4-dihidropiridīna-3,5-dikarboksilātu. Sintezēti pieci jauni kandidātsavienojumi gēnu terapijai, aizvietojot bromu didodecil 2,6-bis((4-(brommetil)-1H-1,2,3-triazol-1-il)metil)-4-fenil-1,4-dihidropiridīna-3,5-dikarboksilātā ar dažādiem piridīniem. Noteikta kritiskā micellu koncentrācija, izmantojot dinamiskās gaismas izkliedes metodi. …

Improvement of fibrinolysis and plasma lipoprotein levels induced by gemfibrozil in hypertriglyceridemia.

1995

A randomized double-blind study was carried out with gemfibrozil (600 mg b.i.d.) vs placebo in 20 patients (twelve males and eight females, age 52 +/- 3 years, BMI 24.2 +/- 0.4) suffering from primary hypertriglyceridemia (Fredrickson's type IV). Each group was treated for a 12 week period with gemfibrozil (n = 10) or placebo (n = 10) patients) in a double-blind fashion. Total cholesterol, HDL-cholesterol (HDL-C) and its subfractions (HDL2-C and HDL3-C), blood glucose, Apolipoproteins A1 and B, fibrinogen, plasminogen, factor VII, t-PA:Ag and PAI activity pre- and post-venous occlusion (VO) were determined. In the gemfibrozil-treated group a significant decrease of total cholesterol and tri…

Measuring microfinance performance

2015

MFIs are measured according to two dimensions. One is their outreach to poor people, that is, their ability to provide poor families access to financial services. This is the MFIs’ social mission. The other dimension is their financial sustainability, that is, their ability to pay their employees, lenders, and other suppliers, in short, their ability to produce a profit from their operations. We set out the main microfinance measures and confirm earlier findings that profitability is rather weak in microfinance, and that operational costs constitute a large part of the total costs. We argue that researchers should put more efforts into identifying the MFI’s cost drivers because social outre…

A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adul…

2019

Introduction: This article comprehensively reviews the clinical utility of the serum clozapine/norclozapine (CLO/NCLO) ratio. Areas covered: Fifty-four published studies used this ratio (21 from a PubMed search from onset to 10/21/18 and 33 identified by the authors). To estimate a combined mean of the CLO/NCLO ratio in published studies, a PubMed search on 10/21/18 identified 422 articles leading to 19 included. The systematic review focused on 1) the combined analysis, 2) CYP1A2 activity, 3) clinical response, 4) cognition, and 5) renal function. Expert opinion: Our combined analysis provided a weighted mean CLO/NCLO ratio of 1.73 in 2,317 adult patients from 19 studies, but the range in …

Dr. habil. Phys. profesora Mārča Auziņa biobibliogrāfija

2018

Latvijas Universitātes rektora, habilitētā fizikas doktora, profesora Mārča Auziņa biobibliogrāfiskajā rādītājā ietvertie publicēto darbu (1970- 2018) bibliogrāfiskie apraksti sagrupēti nodaļās: Profesora M. Auziņa monogrāfijas. Profesora M. Auziņa publikācijas zinātniskajos žurnālos un rakstu krājumos. Zinātnisko konferenču, semināru materiāli. Profesora M. Auziņa populārzinātniskie raksti, publicistika, runas. Profesora M. Auziņa rediģētie un recenzētie darbi. Profesora M. Auziņa vadītās un recenzētās disertācijas. Intervijas un sarunas ar profesoru M. Auziņu. Raksti par profesoru M. Auziņu.

Definizioni di malattia,endpoint e risposta terapeutica nel pemfigo;International consensus.Statment e raccomandazioni GIDI e GIPMO

2009

Hemorheologic profile of hyperlipidemic patients treated with gemfibrozil

1996

Abstract We measured the plasma lipid levels and the macrorheologic (whole-blood, plasma, and serum viscosity levels; fibrinogen; hematocrit; mean erythrocyte aggregation; and whole-blood filterability) and microrheologic (erythrocyte membrane fluidity and red cell membrane protein lateral mobility) determinants in a group of 19 hyperlipidemic patients (Fredrickson's classification phenotype IIa, 12 patients; phenotype IV, 4; phenotype IIb, 3) at baseline and after 45 and 90 days of treatment with gemfibrozil (900 mg orally once a day). At baseline we noted statistically significant increases in plasma viscosity level, fibrinogen, and mean erythrocyte aggregation, as well as a statistically…

Effects of gemfibrozil in hyperlipidemic patients with or without diabetes

1993

Abstract Four hundred sixty-one hyperlipidemic men and women, aged 23 to 73 years, with (n = 200) or without (n = 261) non-insulin-dependent diabetes mellitus were included in a study designed to evaluate the efficacy and tolerability of 1,200 mg of gemfibrozil given once daily for 24 weeks. All lipid values improved significantly in both diabetic and nondiabetic patients during treatment. The number of patients with the atherogenic predictor ratio of low-density:high-density lipoprotein cholesterol (HDL-C:LDL-C) >5 decreased by 95% in both patient groups. The number of patients in the highest-risk subgroup with the combination risk factors of LDL-C:HDL-C >5 and triglyceride levels >200 mg/…

Effect of gemfibrozil treatment on fibrinolysis system in patients with hypertriglyceridemia

1992

Abstract The effect of gemfibrozil on lipidic, coagulative, and fibrinolytic pattern was studied in 20 patients with primary type IV hyperlipoproteinemia. After a 4-week stabilization period during which administration of lipid-lowering drugs was stopped and an isocaloric diet (20% protein, 30% fat, and 50% carbohydrates) was prescribed, 20 patients (12 men and 8 women; mean age, 38 ± 4 years; body mass index, 23.4 ± 1.5) suffering from primary hypertriglyceridemia were included in this study and treated for a 12-week period with gemfibrozil (600 mg BID). Every 4 weeks the following parameters were checked: glycemia, triglycerides, total cholesterol, high density lipoprotein-cholesterol, to…